Massively parallel high-order combinatorial genetics in human cells

Nature Biotechnology

Volumn 33, Issue 9, 2015, Pages 952-961

  Wong, Alan S L ^a,b   Choi, Gigi C G ^a,b   Cheng, Allen A ^a,b   Purcell, Oliver ^a,b   Lu, Timothy K ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROLIFERATION; CELLS; CHEMOTHERAPY; CHROMOSOMES; COMPLEX NETWORKS; CYTOLOGY; DISEASES; LIBRARIES; THROUGHPUT;

BASIC SCIENCE; CANCER CELLS; GENETIC COMBINATIONS; HIGH THROUGHPUT; HIGH-THROUGHPUT SEQUENCING; HUMAN CELLS; HUMAN MICRO-RNA; MASSIVELY PARALLELS;

RNA;

GENOMIC DNA; MICRORNA; MICRORNA 128B; MICRORNA 132; MICRORNA 15A; MICRORNA 16 1; MICRORNA 181C; MICRORNA 99B; UNCLASSIFIED DRUG; GENETIC MARKER; TUMOR MARKER;

ARTICLE; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; COMBINATORIAL GENETICS; COMBINATORIAL LIBRARY; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION SYSTEM; GENE REPRESSION; GENETIC ANALYSIS; GENETIC REGULATION; HIGH THROUGHPUT SCREENING; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN GENETICS; INTERACTIONS WITH RNA; LIMIT OF QUANTITATION; NEXT GENERATION SEQUENCING; PHENOTYPE; PRECURSOR; PRIORITY JOURNAL; REPRODUCIBILITY; COMBINATORIAL CHEMISTRY; EXPERIMENTAL NEOPLASM; GENETIC MARKER; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROCEDURES; SEQUENCE ANALYSIS; TUMOR CELL LINE;

BASE SEQUENCE; BIOMARKERS, TUMOR; CELL LINE, TUMOR; COMBINATORIAL CHEMISTRY TECHNIQUES; GENETIC MARKERS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; SEQUENCE ANALYSIS, RNA;

EID: 84941116401     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3326     Document Type: Article

References (61)

1. Dixon, S.J., Costanzo, M., Baryshnikova, A., Andrews, B., Boone, C. Systematic mapping of genetic interaction networks. Annu. Rev. Genet. 43, 601-625 (2009).
2. Vierbuchen, T., Wernig, M. Molecular roadblocks for cellular reprogramming. Mol. Cell 47, 827-838 (2012).
3. Al-Lazikani, B., Banerji, U., Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692 (2012).
4. Zuk, O., Hechter, E., Sunyaev, S.R., Lander, E.S. The mystery of missing heritability: Genetic interactions create phantom heritability. Proc. Natl. Acad. Sci. USA 109, 1193-1198 (2012).
5. Eichler, E.E. et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat. Rev. Genet. 11, 446-450 (2010).
6. Manolio, T.A. et al. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009).
7. Johannessen, C.M. et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504, 138-142 (2013).
8. Voorhoeve, P.M. et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169-1181 (2006).
9. Moffat, J., Sabatini, D.M. Building mammalian signaling pathways with RNAi screens. Nat. Rev. Mol. Cell Biol. 7, 177-187 (2006).
10. Zhou, Y. et al. High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509, 487-491 (2014).
11. Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M.D.C., Yusa, K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32, 267-273 (2014).
12. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
13. Wang, T., Wei, J.J., Sabatini, D.M., Lander, E.S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
14. Metzker, M.L. Sequencing technologies-the next generation. Nat. Rev. Genet. 11, 31-46 (2010).
15. Yu, H. et al. Next-generation sequencing to generate interactome datasets. Nat. Methods 8, 478-480 (2011).
16. Bassik, M.C. et al. A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 152, 909-922 (2013).
17. Engler, C., Kandzia, R., Marillonnet, S. A one pot, one step, precision cloning method with high throughput capability. PLoS ONE 3, e3647 (2008).
18. Gibson, D.G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343-345 (2009).
19. Zelcbuch, L. et al. Spanning high-dimensional expression space using ribosome-binding site combinatorics. Nucleic Acids Res. 41, e98 (2013).
20. Yoo, A.S. et al. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476, 228-231 (2011).
21. Brown, B.D., Naldini, L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 10, 578-585 (2009).
22. Honma, K. et al. RPN2 gene confers docetaxel resistance in breast cancer. Nat. Med. 14, 939-948 (2008).
23. Creighton, C.J. et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 12, R40 (2010).
24. Blower, P.E. et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6, 1483-1491 (2007).
25. Patnaik, S.K. et al. Expression of microRNAs in the NCI-60 cancer cell-lines. PLoS ONE 7, e49918 (2012).
26. Gholami, A.M. et al. Global proteome analysis of the NCI-60 cell line panel. Cell Reports 4, 609-620 (2013).
27. Hsu, S.-D. et al. MiRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 42, D78-D85 (2014).
28. Strezoska, Ž. et al. Optimized PCR conditions and increased shRNA fold representation improve reproducibility of pooled shRNA screens. PLoS ONE 7, e42341 (2012).
29. Bhattacharya, R. et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 69, 9090-9095 (2009).
30. Cheng, A.A., Ding, H., Lu, T.K. Enhanced killing of antibiotic-resistant bacteria enabled by massively parallel combinatorial genetics. Proc. Natl. Acad. Sci. USA 111, 12462-12467 (2014).
31. Kampmann, M., Bassik, M.C., Weissman, J.S. Integrated platform for genome-wide screening and construction of high-density genetic interaction maps in mammalian cells. Proc. Natl. Acad. Sci. USA 110, E2317-E2326 (2013).
32. Pierce, S.E., Davis, R.W., Nislow, C., Giaever, G. Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nat. Protoc. 2, 2958-2974 (2007).
33. Storey, J.D., Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 100, 9440-9445 (2003).
34. Xia, L. et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 123, 372-379 (2008).
35. Kastl, L., Brown, I., Schofield, A.C. MiRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res. Treat. 131, 445-454 (2012).
36. Krek, A. et al. Combinatorial microRNA target predictions. Nat. Genet. 37, 495-500 (2005).
37. Jacobsen, A. et al. Analysis of microRNA-target interactions across diverse cancer types. Nat. Struct. Mol. Biol. 20, 1325-1332 (2013).
38. Lewis, B.P., Burge, C.B., Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20 (2005).
39. Guillamot, M. et al. Cdc14b regulates mammalian RNA polymerase II and represses cell cycle transcription. Sci. Rep. 1, 189 (2011).
40. Huntzinger, E., Izaurralde, E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet. 12, 99-110 (2011).
41. McLornan, D.P., List, A., Mufti, G.J. Applying synthetic lethality for the selective targeting of cancer. N. Engl. J. Med. 371, 1725-1735 (2014).
42. The Cancer Genome Atlas Research Network. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120 (2013).
43. Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. Nature 507, 455-461 (2014).
44. FANTOM Consortium and the RIKEN PMI and CLST (DGT). A promoter-level mammalian expression atlas. Nature 507, 462-470 (2014).
45. Gandhi, S., Wood, N.W. Genome-wide association studies: the key to unlocking neurodegeneration? Nat. Neurosci. 13, 789-794 (2010).
46. Peden, J.F., Farrall, M. Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour. Hum. Mol. Genet. 20, R198-R205 (2011).
47. Gobeil, S., Zhu, X., Doillon, C.J., Green, M.R. A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. Genes Dev. 22, 2932-2940 (2008).
48. Park, J. et al. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature 498, 325-331 (2013).
49. Chia, N.-Y. et al. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature 468, 316-320 (2010).
50. Ebert, M.S., Neilson, J.R., Sharp, P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721-726 (2007).
51. Guttman, M. et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477, 295-300 (2011).
52. Gilbert, L.A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647-661 (2014).
53. Hsu, P.D., Lander, E.S., Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014).
54. Gaj, T., Gersbach, C.A., Barbas, C.F. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405 (2013).
55. Zhu, F. et al. DICE, an efficient system for iterative genomic editing in human pluripotent stem cells. Nucleic Acids Res. 42, e34 (2014).
56. Bruno, I.G. et al. Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. Mol. Cell 42, 500-510 (2011).
57. Klein, M.E. et al. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat. Neurosci. 10, 1513-1514 (2007).
58. Miyamichi, K. et al. Cortical representations of olfactory input by trans-synaptic tracing. Nature 472, 191-196 (2011).
59. Ren, Y. et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci. Transl. Med. 4, 147-112 (2012).
60. Drees, B.L. et al. Derivation of genetic interaction networks from quantitative phenotype data. Genome Biol. 6, R38 (2005).
61. Tong, A.H.Y. et al. Global mapping of the yeast genetic interaction network. Science 303, 808-813 (2004).